Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 112Virus-based gene therapy researchImmunotherapy and Immune ResponsesPoxvirus research and outbreaks

The DOI matches its Crossref record, with a small difference in title or year.

Viral vectors for vaccine applications

Open access
Choi, Youngjoo, Chang, Jun·2013·Clinical and Experimental Vaccine Research
DOI 10.7774/cevr.2013.2.2.97PMC PMC3710930
Open this paper in CoChat — free accountOpen PDF

Abstract

Traditional approach of inactivated or live-attenuated vaccine immunization has resulted in impressive success in the reduction and control of infectious disease outbreaks. However, many pathogens remain less amenable to deal with the traditional vaccine strategies, and more appropriate vaccine strategy is in need. Recent discoveries that led to increased understanding of viral molecular biology and genetics has rendered the used of viruses as vaccine platforms and as potential anti-cancer agents. Due to their ability to effectively induce both humoral and cell-mediated immune responses, viral vectors are deemed as an attractive alternative to the traditional platforms to deliver vaccine antigens as well as to specifically target and kill tumor cells. With potential targets ranging from cancers to a vast number of infectious diseases, the benefits resulting from successful application of viral vectors to prevent and treat human diseases can be immense.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7774/cevr.2013.2.2.97

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 62

  1. Moss, 1984, Nature, 311, 67, 10.1038/311067a0 · DOI
  2. Banchereau, 1998, Nature, 392, 245, 10.1038/32588 · DOI · Paper page
  3. Gabitzsch, 2009, Vaccine, 27, 6394, 10.1016/j.vaccine.2009.06.028 · DOI
  4. Näslund, 2007, J Immunol, 178, 6761, 10.4049/jimmunol.178.11.6761 · DOI
  5. Shott, 2008, Vaccine, 26, 2818, 10.1016/j.vaccine.2008.03.080 · DOI
  6. Schuldt, 2012, Vaccine, 30, 5191, 10.1016/j.vaccine.2012.05.048 · DOI
  7. Bruder, 2010, Vaccine, 28, 3201, 10.1016/j.vaccine.2010.02.024 · DOI
  8. Bruna-Romero, 2004, Vaccine, 22, 3575, 10.1016/j.vaccine.2004.03.050 · DOI
  9. Rodrigues, 1997, J Immunol, 158, 1268, 10.4049/jimmunol.158.3.1268 · DOI
  10. Rodrigues, 1998, Vaccine, 16, 1812, 10.1016/S0264-410X(98)00181-9 · DOI
  11. Barouch, 2010, Curr Opin HIV AIDS, 5, 386, 10.1097/COH.0b013e32833cfe4c · DOI
  12. Rolland, 2009, Retrovirology, 6, O42, 10.1186/1742-4690-6-S3-O42 · DOI
  13. Vogels, 2003, J Virol, 77, 8263, 10.1128/JVI.77.15.8263-8271.2003 · DOI
  14. Abbink, 2007, J Virol, 81, 4654, 10.1128/JVI.02696-06 · DOI · Paper page
  15. Choi, 2013, Cancer Gene Ther, 20, 70, 10.1038/cgt.2012.95 · DOI
  16. Kirn, 2001, Expert Opin Biol Ther, 1, 525, 10.1517/14712598.1.3.525 · DOI
  17. Kirn, 2001, Gene Ther, 8, 89, 10.1038/sj.gt.3301377 · DOI · Paper page
  18. Nemunaitis, 2000, Cancer Res, 60, 6359
  19. Khuri, 2000, Nat Med, 6, 879, 10.1038/78638 · DOI
  20. Liu, 2008, Gene Ther, 15, 877, 10.1038/gt.2008.72 · DOI
  21. Pesonen, 2011, Mol Pharm, 8, 12, 10.1021/mp100219n · DOI
  22. Alemany, 2007, Mol Aspects Med, 28, 42, 10.1016/j.mam.2006.12.002 · DOI
  23. Ganly, 2000, Clin Cancer Res, 6, 798
  24. Hermiston, 2002, Cancer Gene Ther, 9, 1022, 10.1038/sj.cgt.7700542 · DOI
  25. Toth, 2010, Expert Opin Biol Ther, 10, 353, 10.1517/14712590903559822 · DOI
  26. Crompton, 2007, Curr Cancer Drug Targets, 7, 133, 10.2174/156800907780058862 · DOI
  27. Shashkova, 2007, Mol Ther, 15, 598, 10.1038/sj.mt.6300064 · DOI
  28. Lee, 2006, Clin Cancer Res, 12, 5859, 10.1158/1078-0432.CCR-06-0935 · DOI
  29. Crittenden, 2003, Cancer Res, 63, 5505
  30. Lundstrom, 2005, Gene Ther, 12, S92, 10.1038/sj.gt.3302620 · DOI
  31. Davis, 2002, IUBMB Life, 53, 209, 10.1080/15216540212657 · DOI
  32. Greer, 2007, Vaccine, 25, 481, 10.1016/j.vaccine.2006.07.048 · DOI
  33. Barnett, 2010, J Virol, 84, 5975, 10.1128/JVI.02533-09 · DOI · Paper page
  34. Greer, 2007, Scand J Immunol, 66, 645, 10.1111/j.1365-3083.2007.02019.x · DOI
  35. Mok, 2007, J Virol, 81, 13710, 10.1128/JVI.01351-07 · DOI
  36. Pan, 2010, J Virol, 84, 3798, 10.1128/JVI.01566-09 · DOI
  37. Levine, 1993, Nature, 361, 739, 10.1038/361739a0 · DOI · Paper page
  38. Leitner, 2003, Nat Med, 9, 33, 10.1038/nm813 · DOI · Paper page
  39. Perri, 2003, J Virol, 77, 10394, 10.1128/JVI.77.19.10394-10403.2003 · DOI · Paper page
  40. Gupta, 2006, AIDS Res Hum Retroviruses, 22, 993, 10.1089/aid.2006.22.993 · DOI
  41. Xu, 2006, AIDS Res Hum Retroviruses, 22, 1022, 10.1089/aid.2006.22.1022 · DOI
  42. Colmenero, 1999, Gene Ther, 6, 1728, 10.1038/sj.gt.3301004 · DOI
  43. Ni, 2005, Cancer Immunol Immunother, 54, 489, 10.1007/s00262-004-0591-z · DOI
  44. Kim, 2012, Expert Opin Biol Ther, 12, 463, 10.1517/14712598.2012.668516 · DOI
  45. Moss, 1987, Annu Rev Immunol, 5, 305, 10.1146/annurev.iy.05.040187.001513 · DOI
  46. Bernards, 1987, Proc Natl Acad Sci U S A, 84, 6854, 10.1073/pnas.84.19.6854 · DOI
  47. Hareuveni, 1990, Proc Natl Acad Sci U S A, 87, 9498, 10.1073/pnas.87.23.9498 · DOI
  48. Kaufman, 1991, Int J Cancer, 48, 900, 10.1002/ijc.2910480618 · DOI
  49. Lathe, 1987, Nature, 326, 878, 10.1038/326878a0 · DOI
  50. Meneguzzi, 1990, Vaccine, 8, 199, 10.1016/0264-410X(90)90045-N · DOI
  51. Conry, 1999, Clin Cancer Res, 5, 2330
  52. Tsang, 1995, J Natl Cancer Inst, 87, 982, 10.1093/jnci/87.13.982 · DOI · Paper page
  53. Marshall, 2000, J Clin Oncol, 18, 3964, 10.1200/JCO.2000.18.23.3964 · DOI
  54. Madan, 2007, Expert Opin Biol Ther, 7, 543, 10.1517/14712598.7.4.543 · DOI
  55. Parrino, 2006, J Allergy Clin Immunol, 118, 1320, 10.1016/j.jaci.2006.09.037 · DOI
  56. Rerks-Ngarm, 2009, N Engl J Med, 361, 2209, 10.1056/NEJMoa0908492 · DOI
  57. Harari, 2008, J Exp Med, 205, 63, 10.1084/jem.20071331 · DOI · Paper page
  58. Bart, 2008, Vaccine, 26, 3153, 10.1016/j.vaccine.2008.03.083 · DOI
  59. Sandstöom, 2008, J Infect Dis, 198, 1482, 10.1086/592507 · DOI
  60. Webster, 2005, Proc Natl Acad Sci U S A, 102, 4836, 10.1073/pnas.0406381102 · DOI
  61. Ibanga, 2006, Lancet Infect Dis, 6, 522, 10.1016/S1473-3099(06)70552-7 · DOI
  62. McShane, 2004, Nat Med, 10, 1240, 10.1038/nm1128 · DOI · Paper page

Cited by

See all 112

Metadata

Authors
Choi, Y., & Chang, J.
Affiliations
Ewha Womans University (KR)
Corresponding author
Chang, Jun
ORCID
Venue
Clinical and Experimental Vaccine Research
Publisher
XMLink
Published
2013
Volume
2
Issue
2
Pages
97
ISSN
  • 2287-3651 (ISSN-L)
  • 2287-366X
DOI
10.7774/cevr.2013.2.2.97
PMC
PMC3710930
OpenAlex
W2120183880
Cited by
112
References
0
Citations by year
2026: 2 · 2025: 8 · 2024: 8 · 2023: 10 · 2022: 15 · 2021: 16 · 2020: 17 · 2019: 5 · 2018: 4 · 2017: 6 · 2016: 10 · 2015: 6 · 2014: 3 · 2013: 2
FWCI
4.64
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/3.0/ (tdm)
Locations
  • Clinical and Experimental Vaccine Research (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Ministry of Education, Science and Technology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
Keywords
viral vectors, vaccine platforms, vaccine antigens, cancer vaccines, tumor cell targeting, humoral immune response, cell-mediated immunity, infectious disease vaccines, inactivated vaccine, live attenuated vaccine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Viral vectors for vaccine applications. https://app.cochat.ai/papers/10.7774/cevr.2013.2.2.97
The paper
Choi, Y., & Chang, J. (2013). Viral vectors for vaccine applications. Clinical and Experimental Vaccine Research. https://doi.org/10.7774/cevr.2013.2.2.97

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.